• 1.

    Amusategui I, Sainz A, Tesouro MA. Effects of antimonial therapy for canine leishmaniasis on antibody titer. Ann N Y Acad Sci 1998;849:444446.

    • Search Google Scholar
    • Export Citation
  • 2.

    Amusategui I, Sainz A, Tesouro MA. Evolution of serum albumin/globulin ratio after antimonial therapy in canine leishmaniasis. Ann N Y Acad Sci 1998;849:447449.

    • Search Google Scholar
    • Export Citation
  • 3.

    Paltrinieri S, Solano-Gallego L & Fondati A, et al. Guidelines for diagnosis and clinical classification of leishmaniasis in dogs. J Am Vet Med Assoc 2010;236:11841191.

    • Search Google Scholar
    • Export Citation
  • 4.

    Aste G, Di Tommaso M & Steiner JM, et al. Pancreatitis associated with N-methyl-glucamine therapy in a dog with leishmaniasis. Vet Res Commun 2005;29 (suppl 2):269272.

    • Search Google Scholar
    • Export Citation
  • 5.

    Barbosa Santos EG, Marzochi MC & Conceição NF, et al. N-methylglucamine antimonate (SbV+): intralesional canine tegumentary leishmaniasis therapy. Parasite 1998;5:175180.

    • Search Google Scholar
    • Export Citation
  • 6.

    Belloli C, Ceci L & Carli S, et al. Disposition of antimony and aminosidine in dogs after administration separately and together: implications for therapy of leishmaniasis. Res Vet Sci 1995;58:123127.

    • Search Google Scholar
    • Export Citation
  • 7.

    Bourdoiseau G, Bonnefont C & Hoareau E, et al. Specific IgG1 and IgG2 antibody and lymphocyte subset levels in naturally Leishmania infantum-infected treated and untreated dogs. Vet Immunol Immunopathol 1997;59:2130.

    • Search Google Scholar
    • Export Citation
  • 8.

    Carrió J, Riera C & Gállego M, et al. In vitro activity of pentavalent antimony derivatives on promastigotes and intracellular amastigotes of Leishmania infantum strains from humans and dogs in Spain. Acta Trop 2001;79:179183.

    • Search Google Scholar
    • Export Citation
  • 9.

    Chapman WL Jr, Hanson WL & Alving CR, et al. Antileishmanial activity of liposome-encapsulated meglumine antimonate in the dog. Am J Vet Res 1984;45:10281030.

    • Search Google Scholar
    • Export Citation
  • 10.

    Gradoni L, Maroli M & Gramiccia M, et al. Leishmania infantum infection rates in Phlebotomus perniciosus fed on naturally infected dogs under antimonial treatment. Med Vet Entomol 1987;1:339342.

    • Search Google Scholar
    • Export Citation
  • 11.

    Gramiccia M, Gradoni L, Orsini S. Decreased sensitivity to meglumine antimoniate (Glucantime) of Leishmania infantum isolated from dogs after several courses of drug treatment. Ann Trop Med Parasitol 1992;86:613620.

    • Search Google Scholar
    • Export Citation
  • 12.

    Guarga JL, Moreno J & Lucientes J, et al. Evaluation of a specific immunochemotherapy for the treatment of canine visceral leishmaniasis. Vet Immunol Immunopathol 2002;88:1320.

    • Search Google Scholar
    • Export Citation
  • 13.

    Ikeda-Garcia FA, Lopes RS & Ciarlini PC, et al. Evaluation of renal and hepatic functions in dogs naturally infected by visceral leishmaniasis submitted to treatment with meglumine antimoniate. Res Vet Sci 2007;83:105108.

    • Search Google Scholar
    • Export Citation
  • 14.

    Ikeda-Garcia FA, Lopes RS & Marques FJ, et al. Clinical and parasitological evaluation of dogs naturally infected by Leishmania (Leishmania) chagasi submitted to treatment with meglumine antimoniate. Vet Parasitol 2007;143:254259.

    • Search Google Scholar
    • Export Citation
  • 15.

    Mancianti F, Gramiccia M & Gradoni L, et al. Studies on canine leishmaniasis control. 1. Evolution of infection of different clinical forms of canine leishmaniasis following antimonial treatment. Trans R Soc Trop Med Hyg 1988;82:566567.

    • Search Google Scholar
    • Export Citation
  • 16.

    Moritz A, Steuber S, Greiner M. Clinical follow-up examination after treatment of canine leishmaniasis. Tokai J Exp Clin Med 1998;23:279283.

    • Search Google Scholar
    • Export Citation
  • 17.

    Oliva G, Gradoni L & Cortese L, et al. Comparative efficacy of meglumine antimoniate and aminosidine sulphate, alone or in combination, in canine leishmaniasis. Ann Trop Med Parasitol 1998;92:165171.

    • Search Google Scholar
    • Export Citation
  • 18.

    Riera C, Valladares JE & Gállego M, et al. Serological and parasitological follow-up in dogs experimentally infected with Leishmania infantum and treated with meglumine antimoniate. Vet Parasitol 1999;84:3347.

    • Search Google Scholar
    • Export Citation
  • 19.

    Schettini DA, Costa Val AP & Souza LF, et al. Pharmacokinetic and parasitological evaluation of the bone marrow of dogs with visceral leishmaniasis submitted to multiple dose treatment with liposome-encapsulated meglumine antimoniate. Braz J Med Biol Res 2005;38:18791883.

    • Search Google Scholar
    • Export Citation
  • 20.

    Slappendel RJ, Teske E. The effect of intravenous or subcutaneous administration of meglumine antimonate (Glucantime) in dogs with leishmaniasis. A randomized clinical trial. Vet Q 1997;19:1013.

    • Search Google Scholar
    • Export Citation
  • 21.

    Steuber S, Moritz A & Schirrmann I, et al. PCR follow-up examination after treatment of canine leishmaniosis (CanL). Tokai J Exp Clin Med 1998;23:285292.

    • Search Google Scholar
    • Export Citation
  • 22.

    Tassi P, Ormas P & Madonna M, et al. Pharmacokinetics of N-methylglucamine antimoniate after intravenous, intramuscular and subcutaneous administration in the dog. Res Vet Sci 1994;56:144150.

    • Search Google Scholar
    • Export Citation
  • 23.

    Valladares JE, Alberola J & Esteban M, et al. Disposition of antimony after the administration of N-methylglucamine antimoniate to dogs. Vet Rec 1996;138:181183.

    • Search Google Scholar
    • Export Citation
  • 24.

    Valladares JE, Riera C & González-Ensenyat P, et al. Long term improvement in the treatment of canine leishmaniosis using an antimony liposomal formulation. Vet Parasitol 2001;97:1521.

    • Search Google Scholar
    • Export Citation
  • 25.

    Vouldoukis I, Drapier JC & Nüssler AK, et al. Canine visceral leishmaniasis: successful chemotherapy induces macrophage antileishmanial activity via the L-arginine nitric oxide pathway. Antimicrob Agents Chemother 1996;40:253256.

    • Search Google Scholar
    • Export Citation
  • 26.

    Vouldoukis I, Rougier S & Dugas B, et al. Canine visceral leishmaniasis: comparison of in vitro leishmanicidal activity of marbofloxacin, meglumine antimoniate and sodium stibogluconate. Vet Parasitol 2006;135:137146.

    • Search Google Scholar
    • Export Citation
  • 27.

    Cortese L, Pelagalli A & Piantedosi D, et al. The effects of prednisone on haemostasis in leishmaniotic dogs treated with meglumine antimoniate and allopurinol. Vet J 2008;177:405410.

    • Search Google Scholar
    • Export Citation
  • 28.

    Denerolle P, Bourdoiseau G. Combination allopurinol and antimony treatment versus antimony alone and allopurinol alone in the treatment of canine leishmaniasis (96 cases). J Vet Intern Med 1999;13:413415.

    • Search Google Scholar
    • Export Citation
  • 29.

    Fernández-Pérez FJ, Gómez-Muñoz MT & Méndez S, et al. Leishmania-specific lymphoproliferative responses and IgG1/IgG2 immunodetection patterns by Western blot in asymptomatic, symptomatic and treated dogs. Acta Trop 2003;86:8391.

    • Search Google Scholar
    • Export Citation
  • 30.

    Ferrer L, Aisa MJ & Roura X, et al. Serological diagnosis and treatment of canine leishmaniasis. Vet Rec 1995;136:514516.

  • 31.

    Manna L, Reale S & Vitale F, et al. Real-time PCR assay in Leishmania-infected dogs treated with meglumine antimoniate and allopurinol. Vet J 2008;177:279282.

    • Search Google Scholar
    • Export Citation
  • 32.

    Martínez-Subiela S, Bernal LJ, Cerón JJ. Serum concentrations of acute-phase proteins in dogs with leishmaniosis during short-term treatment. Am J Vet Res 2003;64:10211026.

    • Search Google Scholar
    • Export Citation
  • 33.

    Miranda S, Martorell S & Costa M, et al. Characterization of circulating lymphocyte subpopulations in canine leishmaniasis throughout treatment with antimonials and allopurinol. Vet Parasitol 2007;144:251260.

    • Search Google Scholar
    • Export Citation
  • 34.

    Rodríguez A, Solano-Gallego L & Ojeda A, et al. Dynamics of Leishmania-specific immunoglobulin isotypes in dogs with clinical leishmaniasis before and after treatment. J Vet Intern Med 2006;20:495498.

    • Search Google Scholar
    • Export Citation
  • 35.

    Solano-Gallego L, Riera C & Roura X, et al. Leishmania infantum-specific IgG, IgG1 and IgG2 antibody responses in healthy and ill dogs from endemic areas. Evolution in the course of infection and after treatment. Vet Parasitol 2001;96:265276.

    • Search Google Scholar
    • Export Citation
  • 36.

    Cavaliero T, Arnold P & Mathis A, et al. Clinical, serologic, and parasitologic follow-up after long-term allopurinol therapy of dogs naturally infected with Leishmania infantum. J Vet Intern Med 1999;13:330334.

    • Search Google Scholar
    • Export Citation
  • 37.

    Gothe R, Nolte I, Kraft W. Leishmaniasis in dogs in Germany: epidemiological case analysis and alternatives to conventional causal therapy. Tierarztl Prax 1997;25:6873.

    • Search Google Scholar
    • Export Citation
  • 38.

    Liste F, Gascon M. Allopurinol in the treatment of canine visceral leishmaniasis. Vet Rec 1995;137:2324.

  • 39.

    Pasa S, Toz SO & Voyvoda H, et al. Clinical and serological followup in dogs with visceral leishmaniosis treated with allopurinol and sodium stibogluconate. Vet Parasitol 2005;128:243249.

    • Search Google Scholar
    • Export Citation
  • 40.

    Pennisi MG, Reale S & Giudice SL, et al. Real-time PCR in dogs treated for leishmaniasis with allopurinol. Vet Res Commun 2005;29 (suppl 2):301303.

    • Search Google Scholar
    • Export Citation
  • 41.

    Plevraki K, Koutinas AF & Kaldrymidou H, et al. Effects of allopurinol treatment on the progression of chronic nephritis in Canine leishmaniosis (Leishmania infantum). J Vet Intern Med 2006;20:228233.

    • Search Google Scholar
    • Export Citation
  • 42.

    Sasanelli M, Paradies P & de Caprariis D, et al. Acute-phase proteins in dogs naturally infected with Leishmania infantum during and after long-term therapy with allopurinol. Vet Res Commun 2007;31 (suppl 1):335338.

    • Search Google Scholar
    • Export Citation
  • 43.

    Vercammen F, DeDeken R. Antibody kinetics during allopurinol treatment in canine leishmaniasis. Vet Rec 1996;139:264.

  • 44.

    Vercammen F, De Deken R. Treatment of canine visceral leishmaniasis with allopurinol. Vet Rec 1995;137:252.

  • 45.

    Vercammen F, Fernandez-Perez FJ & del Amo C, et al. Follow-up of Leishmania infantum naturally infected dogs treated with allopurinol: immunofluorescence antibody test, ELISA and Western blot. Acta Trop 2002;84:175181.

    • Search Google Scholar
    • Export Citation
  • 46.

    Poli A, Sozzi S & Guidi G, et al. Comparison of aminosidine (paromomycin) and sodium stibogluconate for treatment of canine leishmaniasis. Vet Parasitol 1997;71:263271.

    • Search Google Scholar
    • Export Citation
  • 47.

    Vexenat JA, Olliaro PL & Fonseca de Castro JA, et al. Clinical recovery and limited cure in canine visceral leishmaniasis treated with aminosidine (paromomycin). Am J Trop Med Hyg 1998;58:448453.

    • Search Google Scholar
    • Export Citation
  • 48.

    Cortadellas O. Initial and long-term efficacy of a lipid emulsion of amphotericin B desoxycholate in the management of canine leishmaniasis. J Vet Intern Med 2003;17:808812.

    • Search Google Scholar
    • Export Citation
  • 49.

    Lamothe J. Activity of amphotericin B in lipid emulsion in the initial treatment of canine leishmaniasis. J Small Anim Pract 2001;42:170175.

    • Search Google Scholar
    • Export Citation
  • 50.

    Oliva G, Gradoni L & Ciaramella P, et al. Activity of liposomal amphotericin B (AmBisome) in dogs naturally infected with Leishmania infantum. J Antimicrob Chemother 1995;36:10131019.

    • Search Google Scholar
    • Export Citation
  • 51.

    Manna L, Vitale F & Reale S, et al. Study of efficacy of miltefosine and allopurinol in dogs with leishmaniosis. Vet J 2009;182:441445.

  • 52.

    Mirò G, Oliva G & Cruz I, et al. Multi-centre and controller clinical field study to evaluate the efficacy and safety of the combination of miltefosine and allopurinol in the treatment of canine leishmaniosis. Vet Dermatol 2008;19 (suppl 1):78.

    • Search Google Scholar
    • Export Citation
  • 53.

    Mateo M, Maynard L & Vischer C, et al. Comparative study on the short term efficacy and adverse effects of miltefosine and meglumine antimoniate in dogs with natural leishmaniosis. Parasitol Res 2009;105:155162.

    • Search Google Scholar
    • Export Citation
  • 54.

    Rhalem A, Sahibi H & Lasri S, et al. Analysis of immune responses in dogs with canine visceral leishmaniasis before, and after, drug treatment. Vet Immunol Immunopathol 1999;71:6976.

    • Search Google Scholar
    • Export Citation
  • 55.

    Pennisi MG, De Majo M & Masucci M, et al. Efficacy of the treatment of dogs with leishmaniosis with a combination of metronidazole and spiramycin. Vet Rec 2005;156:346349.

    • Search Google Scholar
    • Export Citation
  • 56.

    Rougier S, Vouldoukis I & Fournell S, et al. Efficacy of different treatment regimens of marbofloxacin in canine visceral leishmaniosis: a pilot study. Vet Parasitol 2008;153:244254.

    • Search Google Scholar
    • Export Citation
  • 57.

    Bianciardi P, Fasanella A & Foglia Manzillo V, et al. The efficacy of enrofloxacin, alone or combined with metronidazole, in the therapy of canine leishmaniasis. Parasitol Res 2004;93:486492.

    • Search Google Scholar
    • Export Citation
  • 58.

    Gómez-Ochoa P, Castillo JA & Gascón M, et al. Use of domperidone in the treatment of canine visceral leishmaniasis: a clinical trial. Vet J 2009;179:259263.

    • Search Google Scholar
    • Export Citation
  • 59.

    Gradoni L, Bryceson A, Desjeux P. Treatment of Mediterranean visceral leishmaniasis. Bull World Health Organ 1995;73:191197.

  • 60.

    Gradoni L, Gramiccia M, Scalone A. Visceral leishmaniasis treatment, Italy. Emerg Infect Dis 2003;9:16171620.

  • 61.

    Shapiro TA, Were JB & Danso K, et al. Pharmacokinetics and metabolism of allopurinol riboside. Clin Pharmacol Ther 1991;49:506514.

  • 62.

    Di Martino L, Mantovani MP & Gradoni L, et al. Low dosage combination of meglumine antimoniate plus allopurinol as first choice treatment of infantile visceral leishmaniasis in Italy. Trans R Soc Trop Med Hyg 1990;84:534535.

    • Search Google Scholar
    • Export Citation
  • 63.

    Sundar S, Rai M. Advances in the treatment of leishmaniasis. Curr Opin Infect Dis 2002;15:593598.

  • 64.

    Davidson RN, den Boer M, Ritmeijer K. Paromomycin. Trans R Soc Trop Med Hyg 2009;103:653660.

  • 65.

    Davidson RN. Practical guide for the treatment of leishmaniasis. Drugs 1998;56:10091018.

  • 66.

    Sindermann H, Engel J. Development of miltefosine as an oral treatment for leishmaniasis. Trans R Soc Trop Med Hyg 2006;100 (suppl 1):S17S20.

    • Search Google Scholar
    • Export Citation
  • 67.

    Croft SL, Neal RA & Pendergast W, et al. The activity of alkylphosphorylcholines and related derivatives against Leishmania donovani. Biochem Pharmacol 1987;36:26332666.

    • Search Google Scholar
    • Export Citation
  • 68.

    Kuhlencord A, Maniera T & Eibl H, et al. Hexadecylphosphocholine: oral treatment of visceral leishmaniasis in mice. Antimicrob Agents Chemother 1992;36:16301634.

    • Search Google Scholar
    • Export Citation
  • 69.

    Jha TK, Sundar S & Thakur CP, et al. Miltefosine, an oral agent, for the treatment of Indian Visceral Leishmaniasis. N Engl J Med 1999;341:17951800.

    • Search Google Scholar
    • Export Citation
  • 70.

    Sundar S, Chatteryee M. Visceral leishmaniasis-current therapeutic modalities. Indian J Med Res 2006;123:345352.

  • 71.

    Jha SN, Singh NKP, Jha TK. Changing response to diamidine compound in cases of kala-azar unresponsive to antimonials. J Assoc Physicians India 1991;39:314316.

    • Search Google Scholar
    • Export Citation
  • 72.

    Berczi I, Bertok L, Chow DA. Natural immunity and neuroimmune host defense. Ann N Y Acad Sci 2000;917:248257.

  • 73.

    Hinterberger-Fischer M. Prolactin as pro-inflammatory cytokine. Consideration on consolidated immunotherapy after high dosage therapy. Acta Med Austriaca Suppl 2000;52:1620.

    • Search Google Scholar
    • Export Citation

Advertisement

Guidelines for treatment of leishmaniasis in dogs

View More View Less
  • 1 Department of Veterinary Clinical Sciences, Faculty of Veterinary Medicine, University of Naples, 80137 Naples, Italy.
  • | 2 Veterinary Teaching Hospital, College of Veterinary Medicine, Universitat Autònoma de Barcelona, 08007 Barcelona, Spain.
  • | 3 Associated Veterinary Clinic, Via P. Revelli Beaumont 43, 16143 Genoa, Italy.
  • | 4 Vector-borne Diseases & International Health, MIPI Department, National Institute of Health, Viale Regina Elena, 00161 Rome, Italy.
  • | 5 Department of Public Health, Comparative Pathology & Veterinary Hygiene, Faculty of Veterinary Medicine, University of Padua, 35020 Legnaro, Italy.
  • | 6 Vector-borne Diseases & International Health, MIPI Department, National Institute of Health, Viale Regina Elena, 00161 Rome, Italy.
  • | 7 Department of Veterinary Clinic, Faculty of Veterinary Medicine, University of Pisa, 56126 Pisa, Italy.
  • | 8 Department of Veterinary Pathology, Hygiene and Public Health, School of Veterinary Medicine, University of Milan, 20122 Milan, Italy.
  • | 9 Veterinary Clinic Pirani, Via Majakowski 2/L,M,N, 42100 Reggio Emilia, Italy.
  • | 10 Clinic for Small Animal Internal Medicine, Vetsuisse Faculty, University of Zurich, CH 8057 Zurich, Switzerland.

Contributor Notes

Supported by Hill's Pet Nutrition Incorporated.

All authors contributed equally to the study.

Address correspondence to Dr. Zini (ezini@vetclinics.uzh.ch).